| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3244ba8390b1f290f4ba36389c82488b |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-49
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-43
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-715
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-49
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
1995-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f4fef20fa1f616cf7c48bcff83e4cddb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_394504e10db39903b283015c05af388d |
| publicationDate |
2001-09-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
UA-41398-C2 |
| titleOfInvention |
PATIENT TREATMENT METHOD AND METHOD reduce the risk of bleeding and brain hemorrhage in patients requiring thrombolytic therapy, PHARMACEUTICAL COMBINATION IN THE FORM ADVANCE packed unit and pharmaceutical packaging unit consisting of this combination |
| abstract |
This invention relates to compositions and methods for treating patients with acute occlusive vascular disease. A method of treating a patient in need of thrombolytic therapy by administering a pharmaceutical combination containing an effective amount of a thrombolytically active protein, the thrombolytically active protein having a half-life twice that of a human tissue-type plasminogen activator. The protein is administered by bolus injection, and the pharmaceutical combination used in the treatment includes a non-heparin anticoagulant in combination with said thrombolytically active protein, and said non-heparin anticoagulant is presented in a form that allows administration of said anticoagulant by at least one intravenous injection loading dose. |
| priorityDate |
1994-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |